| Administration of tumor infiltrating lymphocytes with membrane bound interleukin 15 to treat cancer M Khattar, S Subramanian, R Burga, ML Ols, J Ter Meulen, K Pedro, ... US Patent App. 18/501,621, 2024 | | 2024 |
| Abstract LB072: Tumor-infiltrating lymphocytes (TIL) engineered with membrane-bound IL15 (cytoTIL15 cells) exhibit pharmacologically regulatable signal transduction in cis and … R Burga, G Kulkarni, Z Ao, DK Sethi, J ter Meulen, M Ols Cancer Research 84 (7_Supplement), LB072-LB072, 2024 | | 2024 |
| Abstract LB065: Tumor-infiltrating lymphocytes (TIL) engineered with regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) show enhanced efficacy in fibroblast … B Koscso, Z Ao, C Passaro, N Shah, N Ly, P Timpug, BA Aksoy, D Sun, ... Cancer Research 84 (7_Supplement), LB065-LB065, 2024 | | 2024 |
| Tumor-infiltrating lymphocytes with membrane bound interleukin 15 and uses thereof K Pedro, JA Storer, J Ter Meulen, R Burga, M Khattar, OLS Michelle, ... US Patent App. 18/261,765, 2024 | | 2024 |
| Toll-like receptor 4 agonist injection with concurrent radiotherapy in patients with metastatic soft tissue sarcoma: a phase 1 nonrandomized controlled trial YD Seo, H Lu, G Black, K Smythe, Y Yu, C Hsu, J Ng, PH De Viveiros, ... JAMA oncology 9 (12), 1660-1668, 2023 | 9 | 2023 |
| Post-Exposure Vaccination Against Viral Respiratory Infections J Ter Meulen, J Rohayem, R Horlacher US Patent App. 18/005,780, 2023 | | 2023 |
| Abstract LB096: IL15-engineered tumor infiltrating lymphocytes (cytoTIL15TM) exhibit activity against autologous tumor cells from multiple solid tumor indications … KD Pedro, R Burga, AV Ocando, M Langley, G Kulkarni, Z Ao, B Primack, ... Cancer Research 83 (8_Supplement), LB096-LB096, 2023 | 1 | 2023 |
| Abstract LB093: Engineering tumor infiltrating lymphocytes from sarcoma and colorectal tumors with membrane bound IL-15 for IL-2 independent expansion and enhanced cytotoxicity … Z Ao, C Passaro, BA Aksoy, B Koscso, R Burga, K Pedro, N Ly, N Shah, ... Cancer Research 83 (8_Supplement), LB093-LB093, 2023 | | 2023 |
| Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell … D Horvath, N Temperton, M Mayora-Neto, K Da Costa, D Cantoni, ... Scientific Reports 13 (1), 4648, 2023 | 6 | 2023 |
| TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence … R Burga, AV Ocando, KP Arman Aksoy, G Kulkarni, M Langley, B Primack, ... | | 2023 |
| Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell … JT Meulen, D Horvath, N Temperton, MM Neto, KD Costa, D Cantoni, ... | | 2022 |
| Pharmacologically-controlled expression of membrane-bound IL-12 results in T-cell therapy with enhanced potency in preclinical solid tumor models S Smith, B Primack, T Ross, P Timpug, D Sun, DJ Li, S Lajoie, V Young, ... Journal for ImmunoTherapy of Cancer 10, A293-A293, 2022 | | 2022 |
| Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with … C Passaro, B Koscso, S Smith, V Young, T Ross, B Primack, N Ly, ... J. Immunother. Cancer https://doi. org/10.1136/jitc-2022-sitc2022 369, 2022 | 2 | 2022 |
| Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15 TM therapy) in an allogeneic melanoma PDX model R Burga, Z Ao, A Aksoy, S Lajoie, K Pedro, J Tremblay, G Kulkarni, ... Journal for ImmunoTherapy of Cancer 10, A411-A411, 2022 | | 2022 |
| Lipid nanoparticle vaccine adjuvants and antigen delivery systems M Gindy, DR Casimiro, A Bett, JH Ter Meulen US Patent 11,406,706, 2022 | 1 | 2022 |
| Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof JH Ter Meulen, PLA Berglund, TT Albershardt US Patent 11,365,230, 2022 | | 2022 |
| Allogeneic, IL-2-independent tumor-infiltrating lymphocytes expressing membrane-bound IL-15 (cytoTIL15 (TM)) eradicate tumors in a melanoma PDX model through recognition of … JH Tchaicha, S Lajoie, R Burga, T Ross, B Primack, M Langley, V Young, ... CANCER RESEARCH 82 (12), 2022 | | 2022 |
| Abstract LB212: Allogeneic, IL-2-independent tumor-infiltrating lymphocytes expressing membrane-bound IL-15 (cytoTIL15࣪) eradicate tumors in a melanoma PDX model through … JH Tchaicha, S Lajoie, R Burga, T Ross, B Primack, M Langley, V Young, ... Cancer Research 82 (12_Supplement), LB212-LB212, 2022 | 1 | 2022 |
| Abstract LB101: Novel Drug-responsive domain (DRD)-based regulation technology enables tightly controlled activity of potent membrane-bound IL12 in adoptive cell therapies SG Smith, JA Storer, D Sun, DJ Li, B Primack, T Ross, S LaJoie, ... Cancer Research 82 (12_Supplement), LB101-LB101, 2022 | | 2022 |
| Administration of tumor infiltrating lymphocytes with membrane bound interleukin 15 to treat cancer M Khattar, S Subramanian, R Burga, ML Ols, J Ter Meulen, K Pedro, ... US Patent App. 17/577,940, 2022 | | 2022 |
